Publications

Gupta, S., Termini, J.M., Issac, B., Guirado, E., and Stone, G.W. Constitutively active MAVS inhibits HIV-1 replication via Type I interferon secretion and induction of HIV-1 restriction factors. PLoS ONE 11(2):e0148929, 2016.
IPS-1 is also called MAVS. This is the first report of LMP-IPS-1, a patent-pending novel gene sequence that activates the STING pathway.

Gupta, S., Termini, J.M., Niu, L., Kanagavelu, S.K., Schmidtmayerova, H., Snarsky, V., Kornbluth, R.S., and Stone, G.W. EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine. J Leukoc Biol. 90:389-398, 2011.
LMP1 mRNA was introduced into dendritic cells (DCs) to make them highly activated for antigen presentation. The LMP1 coding sequence was also genetically inserted into the HIV-1 genome following which this virus became capable of activating DCs to induce strong CD8+ T cell responses.

Gupta, S., Termini, J.M., Niu, L., Kanagavelu, S.K., Rahmberg, A.R., Kornbluth, R.S., Evans, D.T., and Stone, G.W. Latent membrane protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines. Retrovirology 8:39, 2011.
LMP1 is a portable genetic adjuvant cassette that can be introduced into the genome of any viral vaccine. The resulting LMP1-containing virus (which in this case was an attenuated, non-virulent form of SIV) activated DCs to generate strong antiviral CD8+ T cell responses.